Development of engineered magnetic liposome/exosome hybrid as a novel caffeine nanocarrier for restraining liver fibrosis induced in rats

Puntos clave

• Caffeine nanocarrier significantly restrains liver fibrosis in rats, revealing potential benefits.
• The study observed treatment efficacy during a defined experimental period with marked reduction in fibrosis progression.
• Analysis utilized engineered magnetic liposomes combined with exosomal technology for drug delivery in vivo.
• Supports further investigation of this hybrid nanocarrier's therapeutic potential to manage liver diseases in clinical settings.